Symbols

COLL

Collegium·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Consensus Rating "Strong Buy"

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About COLL

Collegium Pharmaceutical, Inc.

A leading specialty pharmaceutical company that develops generic and branded drugs primarily for the treatmet of chronic pain and other diseases

Industry

Pharmaceutical

Established Date

Listing Date

05/07/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

423

Fiscal Year Ends

12-31

Website

www.collegiumpharma.com

Security Type

Common stock

Office address

100 Technology Center Drive Stoughton MA 02072

Business

Introduction

Collegium Pharmaceutical, Inc., was incorporated in Delaware in April 2002 and subsequently re-incorporated in Virginia in July 2014. The company's mission is to build a leading and diversified specialty pharmaceutical company dedicated to improving the lives of critically ill patients. The company has leveraged R&D efforts and acquisition and licensing relationships with third parties to develop a meaningful range of differentiated products for the treatment of moderate to severe pain.

Company Financials

EPS

COLL has released its 2025 Q4 earnings. EPS was reported at 2.04, versus the expected 2.14, missing expectations. The chart below visualizes how COLL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

COLL has released its 2025 Q4 earnings report, with revenue of 205.45M, reflecting a YoY change of 12.92%, and net profit of 16.96M, showing a YoY change of 35.31%. The Sankey diagram below clearly presents COLL's revenue sources and cost distribution.